Novabay Pharmaceuticals (NBY) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Should Novabay Pharmaceuticals’ common stock be delisted from the NYSE American, the company could experience severe repercussions, including reduced market liquidity and considerable challenges in raising additional funds. Limited market quotations and the potential classification as a “penny stock” may lead to stricter trading regulations and diminished trading activity. Moreover, such delisting could trigger defaults under certain debt agreements and increase the risk of costly litigation or regulatory scrutiny, possibly having a profound negative impact on Novabay’s financial health and operational focus.
The average NBY stock price target is $2.60, implying 3,133.83% upside potential.
To learn more about Novabay Pharmaceuticals’ risk factors, click here.
